Larvol Delta - Affimed-Announces-Updated-Phase-12-Data-from-Acimtamig-in-Combination-with-Allogeneic-NK-in-Hodgkin-Lymphoma-Patients-Who-Failed-Prior-Chemotherapy-and-Are-DoubleRefractory-to-Brentuximab-Vedotin-BV-and-Checkpoint-Inhibitors-CPIs

acimtamig (AFM13) - Affimed

https://www.globenewswire.com/news-release/2023/12/11/2793672/0/en/Affimed-Announces-Updated-Phase-1-2-Data-from-Acimtamig-in-Combination-with-Allogeneic-NK-in-Hodgkin-Lymphoma-Patients-Who-Failed-Prior-Chemotherapy-and-Are-Double-Refractory-to-Br.html

Dec 11, 2023

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next